Extended safety tracking for mast cell disorder drug

NCT ID NCT06748001

Summary

This study continues monitoring the safety of avapritinib for people with systemic mastocytosis who previously participated in related trials and are still benefiting from the medication. It tracks side effects and safety issues over a longer period. The goal is to better understand the long-term safety profile of this treatment for this rare condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASTOCYTOSIS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno

    RECRUITING

    Salerno, 84131, Italy

  • Erasmus Medisch Centrum

    RECRUITING

    Rotterdam, 3015, Netherlands

  • Guys and St Thomas NHS Foundation Trust - St Thomas Hospital

    RECRUITING

    London, SE19RT, United Kingdom

  • Oslo University Hospital

    RECRUITING

    Oslo, 0424, Norway

  • The Hospital for Sick Children

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • Universitair Medisch Centrum Groningen

    RECRUITING

    Groningen, 9700, Netherlands

  • Universitair Ziekenhuis Antwerpen (UZA)

    RECRUITING

    Edegem, 2650, Belgium

Conditions

Explore the condition pages connected to this study.